DK3519416T3 - Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf - Google Patents
Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf Download PDFInfo
- Publication number
- DK3519416T3 DK3519416T3 DK17781253.4T DK17781253T DK3519416T3 DK 3519416 T3 DK3519416 T3 DK 3519416T3 DK 17781253 T DK17781253 T DK 17781253T DK 3519416 T3 DK3519416 T3 DK 3519416T3
- Authority
- DK
- Denmark
- Prior art keywords
- mglur2
- isochroman
- chroman
- compositions
- allosteric modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662400150P | 2016-09-27 | 2016-09-27 | |
PCT/US2017/053155 WO2018063955A1 (en) | 2016-09-27 | 2017-09-25 | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3519416T3 true DK3519416T3 (da) | 2021-05-25 |
Family
ID=60043302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17781253.4T DK3519416T3 (da) | 2016-09-27 | 2017-09-25 | Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf |
Country Status (39)
Country | Link |
---|---|
US (4) | US10335399B2 (da) |
EP (1) | EP3519416B1 (da) |
JP (3) | JP6681517B2 (da) |
KR (1) | KR102296043B1 (da) |
CN (1) | CN109983022B (da) |
AR (1) | AR109714A1 (da) |
AU (2) | AU2017334870C1 (da) |
CA (1) | CA3037537C (da) |
CL (1) | CL2019000778A1 (da) |
CO (1) | CO2019002673A2 (da) |
CR (1) | CR20190147A (da) |
CY (1) | CY1124346T1 (da) |
DK (1) | DK3519416T3 (da) |
DO (1) | DOP2019000076A (da) |
EA (1) | EA038627B1 (da) |
EC (1) | ECSP19020742A (da) |
ES (1) | ES2868973T3 (da) |
GE (2) | GEP20217279B (da) |
HR (1) | HRP20210793T1 (da) |
HU (1) | HUE054898T2 (da) |
IL (1) | IL265366B (da) |
JO (1) | JOP20190058B1 (da) |
LT (1) | LT3519416T (da) |
MA (1) | MA46342B1 (da) |
MD (1) | MD3519416T2 (da) |
MX (1) | MX2019003492A (da) |
MY (1) | MY196807A (da) |
NI (1) | NI201900025A (da) |
PE (1) | PE20190609A1 (da) |
PH (1) | PH12019500597A1 (da) |
PL (1) | PL3519416T3 (da) |
PT (1) | PT3519416T (da) |
RS (1) | RS61890B1 (da) |
SI (1) | SI3519416T1 (da) |
TN (2) | TN2020000161A1 (da) |
TW (1) | TWI764934B (da) |
UA (1) | UA123687C2 (da) |
WO (1) | WO2018063955A1 (da) |
ZA (1) | ZA201901701B (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3519416T3 (pl) * | 2016-09-27 | 2021-09-06 | Merck Sharp & Dohme Corp. | Pochodne chromanu, izochromanu i dihydroizobenzofuranu jako ujemne allosteryczne modulatory mglur2, ich kompozycje i zastosowanie |
MA51620A (fr) | 2018-01-19 | 2020-11-25 | Cytokinetics Inc | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques |
US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
BR112021017276A2 (pt) * | 2019-03-01 | 2021-11-09 | Kbp Biosciences Co Ltd | Método para preparar composto tricíclico e intermediário do mesmo |
KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
WO2023278729A1 (en) * | 2021-06-30 | 2023-01-05 | The General Hospital Corporation | Chromane imaging ligands |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
WO2007038865A1 (en) | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
BRPI0917394A2 (pt) | 2008-08-18 | 2019-09-24 | Univ Yale | moduladores de mif |
MY161325A (en) * | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US9278960B2 (en) * | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
US10538491B2 (en) | 2015-03-16 | 2020-01-21 | Vanderbilt University | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators |
JP6471614B2 (ja) | 2015-05-29 | 2019-02-20 | 株式会社リコー | 通信端末、通信システム、通信制御方法、及びプログラム |
JP2018154554A (ja) | 2015-07-29 | 2018-10-04 | 大日本住友製薬株式会社 | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 |
PL3519416T3 (pl) * | 2016-09-27 | 2021-09-06 | Merck Sharp & Dohme Corp. | Pochodne chromanu, izochromanu i dihydroizobenzofuranu jako ujemne allosteryczne modulatory mglur2, ich kompozycje i zastosowanie |
-
2017
- 2017-09-25 PL PL17781253T patent/PL3519416T3/pl unknown
- 2017-09-25 WO PCT/US2017/053155 patent/WO2018063955A1/en active Application Filing
- 2017-09-25 MA MA46342A patent/MA46342B1/fr unknown
- 2017-09-25 PE PE2019000706A patent/PE20190609A1/es unknown
- 2017-09-25 ES ES17781253T patent/ES2868973T3/es active Active
- 2017-09-25 HU HUE17781253A patent/HUE054898T2/hu unknown
- 2017-09-25 CR CR20190147A patent/CR20190147A/es unknown
- 2017-09-25 EA EA201990818A patent/EA038627B1/ru unknown
- 2017-09-25 AR ARP170102642A patent/AR109714A1/es active IP Right Grant
- 2017-09-25 KR KR1020197011789A patent/KR102296043B1/ko active IP Right Grant
- 2017-09-25 PT PT177812534T patent/PT3519416T/pt unknown
- 2017-09-25 AU AU2017334870A patent/AU2017334870C1/en active Active
- 2017-09-25 EP EP17781253.4A patent/EP3519416B1/en active Active
- 2017-09-25 UA UAA201904545A patent/UA123687C2/uk unknown
- 2017-09-25 MY MYPI2019001659A patent/MY196807A/en unknown
- 2017-09-25 CN CN201780071759.0A patent/CN109983022B/zh active Active
- 2017-09-25 GE GEAP201715310A patent/GEP20217279B/en unknown
- 2017-09-25 US US15/713,769 patent/US10335399B2/en active Active
- 2017-09-25 CA CA3037537A patent/CA3037537C/en active Active
- 2017-09-25 GE GEAP201715056A patent/GEP20217266B/en unknown
- 2017-09-25 LT LTEP17781253.4T patent/LT3519416T/lt unknown
- 2017-09-25 JP JP2019516203A patent/JP6681517B2/ja active Active
- 2017-09-25 RS RS20210649A patent/RS61890B1/sr unknown
- 2017-09-25 TW TW106132824A patent/TWI764934B/zh active
- 2017-09-25 TN TNP/2020/000161A patent/TN2020000161A1/en unknown
- 2017-09-25 DK DK17781253.4T patent/DK3519416T3/da active
- 2017-09-25 JO JOP/2019/0058A patent/JOP20190058B1/ar active
- 2017-09-25 TN TNP/2020/000160A patent/TN2020000160A1/en unknown
- 2017-09-25 MX MX2019003492A patent/MX2019003492A/es unknown
- 2017-09-25 SI SI201730727T patent/SI3519416T1/sl unknown
- 2017-09-25 MD MDE20190867T patent/MD3519416T2/ro unknown
-
2019
- 2019-03-13 IL IL265366A patent/IL265366B/en unknown
- 2019-03-19 PH PH12019500597A patent/PH12019500597A1/en unknown
- 2019-03-19 ZA ZA2019/01701A patent/ZA201901701B/en unknown
- 2019-03-20 NI NI201900025A patent/NI201900025A/es unknown
- 2019-03-22 CO CONC2019/0002673A patent/CO2019002673A2/es unknown
- 2019-03-25 CL CL2019000778A patent/CL2019000778A1/es unknown
- 2019-03-26 DO DO2019000076A patent/DOP2019000076A/es unknown
- 2019-03-28 EC ECSENADI201920742A patent/ECSP19020742A/es unknown
- 2019-04-23 US US16/392,131 patent/US10806724B2/en active Active
- 2019-09-30 JP JP2019178232A patent/JP6945605B2/ja active Active
-
2020
- 2020-03-23 JP JP2020051049A patent/JP6992109B2/ja active Active
- 2020-09-25 US US17/032,626 patent/US20210015800A1/en not_active Abandoned
- 2020-11-16 AU AU2020270468A patent/AU2020270468B2/en active Active
-
2021
- 2021-05-17 HR HRP20210793TT patent/HRP20210793T1/hr unknown
- 2021-05-31 CY CY20211100468T patent/CY1124346T1/el unknown
-
2022
- 2022-03-15 US US17/695,262 patent/US20220218676A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3519416T3 (da) | Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf | |
DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
DK3341367T3 (da) | Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer | |
DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
EP3229789A4 (en) | Microencapsulated cannabinoid compositions | |
DK3328849T3 (da) | 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer | |
DK3258942T3 (da) | Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol | |
IL243671B (en) | Sulfonamides for modulating sodium channels, preparations containing them and their uses | |
EP3283080A4 (en) | Compositions for modulating c9orf72 expression | |
DK3363790T3 (da) | 1,2,4-oxadiazolderivater som immunmodulatorer | |
DK3313832T3 (da) | 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere | |
DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
DK3071709T3 (da) | Mikrobiotasammensætning som en markør for modtagelighed over for kemoterapi og anvendelse af mikrobielle modulatorer (præ-, pro- eller synbiotika) til forbedring af virkningsgraden af en cancerbehandling | |
DK3377483T3 (da) | N-substituerede indolderivater som pge2-receptormodulatorer | |
DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
DK3712150T3 (da) | Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf | |
DK3625222T3 (da) | Phenylderivater som pge2-receptormodulatorer | |
DK2861573T3 (da) | Oxathiazin-derivater som antibakterielle og anticancer-stoffer | |
DK3126361T3 (da) | Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer | |
DK3464260T3 (da) | Forbindelser, der indeholder ureamotiver, og derivater deraf som antibakterielle lægemidler | |
EP3185865A4 (en) | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
DK3292105T3 (da) | Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) | |
DK3003493T3 (da) | Enzymatisk system, som indeholder kosmetiske sammensætninger | |
DK3468964T3 (da) | Modulatorer af SOCE, sammensætninger og anvendelser deraf |